BeiGene (NASDAQ: BGNE; HKEX: 06160; SSE: 688235), a global biotechnology company, today announced the China National Medical Products Administration (NMPA)...
A study conducted by the Indian Council of Medical Research (ICMR) in collaboration with the Ministry of Health and Family Welfare, Government of India, wh...
The RESPONSE Power System is a complete portfolio of instruments for tapping pedicles, inserting screws, and final tightening of set screws. RESPONSE Power...
Together, the two companies will provide fully equipped portable Sterile Processing Department (SPD) solutions to a burgeoning US surgical market. The mob...
The EVAQ Trial enrolled 121 patients at 17 centers globally. Data from the study will be used as part of an application to the U.S. Food and Drug Administr...
All India Institute of Medical Sciences (AIIMS) New Delhi and India Medtronic, a wholly owned subsidiary of Ireland-based Medtronic plc, has announced the ...
Transcenta Holding Limited ("Transcenta") (HKEX: 06628), a clinical stage biopharmaceutical company with fully-integrated capabilities in discovery, resear...
The milestone marks the final implantation of the 539th patient enrolled in the prospective, multicenter, randomized, masked, controlled IDE clinical study...
Aurora Cannabis Inc. (the "Company" or "Aurora") (NASDAQ: ACB) (TSX: ACB), the Canadian company opening the world to cannabis, and a leading manufacturer a...
The transaction provides Abbott with a complementary solution for treating vascular disease. CSI's leading atherectomy system prepares vessels for angiopla...
"Our shared vision is one program offered at two sites to provide patients with the right care in a location close to home," said Dr. Glen Van Arsdell, who...
European Commission Approval of Opfolda and Commercial Launch of Pombiliti® + Opfolda® Anticipated in 3Q 2023 Upon Approval, Pombiliti + O...
Indica Labs, an industry leader in quantitative digital pathology and image management innovations, and Lunit, a leading medical AI software platform compa...
QIAGEN (NYSE: QGEN; Frankfurt Prime Standard: QIA) announced today that its QIAstat-Dx syndromic testing solution is expected to be available soon for use ...
© 2024 Biopharma Boardroom. All Rights Reserved.
